We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Heterologous Booster with BNT162b2 Induced High Specific Antibody Levels in CoronaVac Vaccinees.
- Authors
Masson, Letícia Carrijo; Servian, Carolina do Prado; Jardim, Vitor Hugo; dos Anjos, Déborah; Dorta, Miriam Leandro; Batalha-Carvalho, João Victor; Moro, Ana Maria; Romão, Pedro Roosevelt Torres; Souza, Menira; Fiaccadori, Fabiola Souza; Fonseca, Simone Gonçalves
- Abstract
Immune responses after COVID-19 vaccination should be evaluated in different populations around the world. This study compared antibody responses induced by ChAdOx1 nCoV-19, CoronaVac, and BNT162b2 vaccines. Blood samples from vaccinees were collected pre- and post-vaccinations with the second and third doses. The study enrolled 78 vaccinees, of whom 62.8% were women, with the following median ages: 26 years—ChAdOx1 nCoV-19; 40 years—CoronaVac; 30 years—BNT162b2. Serum samples were quantified for anti-RBD IgG and anti-RBD IgA and anti-spike IgG by ELISA. After two vaccine doses, BNT162b2 vaccinees produced higher levels of anti-RBD IgA and IgG, and anti-spike IgG compared to ChAdOx1 nCoV-19 and CoronaVac vaccinees. The third dose booster with BNT162b2 induced higher levels of anti-RBD IgA and IgG, and anti-spike IgG in CoronaVac vaccinees. Individuals who reported a SARS-CoV-2 infection before or during the study had higher anti-RBD IgA and IgG production. In conclusion, two doses of the studied vaccines induced detectable levels of anti-RBD IgA and IgG and anti-spike IgG in vaccinees. The heterologous booster with BNT162b2 increased anti-RBD IgA and IgG and anti-spike IgG levels in CoronaVac vaccinees and anti-RBD IgA levels in ChAdOx1 nCoV-19 vaccinees. Furthermore, SARS-CoV-2 infection induced higher anti-RBD IgA and IgG levels in CoronaVac vaccinees.
- Subjects
COVID-19 vaccines; BOOSTER vaccines; ANTIBODY formation; IMMUNOGLOBULINS; COVID-19 pandemic
- Publication
Vaccines, 2023, Vol 11, Issue 7, p1183
- ISSN
2076-393X
- Publication type
Article
- DOI
10.3390/vaccines11071183